Advanced Search

 

Study ID Status Title Patient Level Data
LPL104884 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subjects with stable coronary heart disease (CHD) or CHD-risk equivalent to examine chronic inhibition of Lp-PLA2 effects on circulating biomarkers associated with cardiovascular risk, safety and tolerability over 12 weeks Study Listed on ClinicalStudyDataRequest.com
LPL107629 Completed A randomised, double-blind, placebo-controlled, parallel group, repeat dose study to assess the effect of SB-480848 on overall asthma control in adult subjects with persistent asthma controlled on stable, low-dose, inhaled corticosteroids Study Listed on ClinicalStudyDataRequest.com
LPL110077 Completed A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of darapladib (SB480848) in healthy Japanese male subjects Study Listed on ClinicalStudyDataRequest.com
LPL110118 Completed A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A multicenter, randomized, double-blind, placebo-controlled study of SB-480848 to evaluate the Efficacy and Safety - Study Listed on ClinicalStudyDataRequest.com
LPL110736 Completed Phase I study of SB-480848 (darapladib) -A double blind, randomised, placebo-controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-480848 in healthy Japanese male subjects- Study Listed on ClinicalStudyDataRequest.com
LPL111814 Completed An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects Study Listed on ClinicalStudyDataRequest.com
LPL112498 Completed A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and its Metabolites in Healthy Volunteers. Study Listed on ClinicalStudyDataRequest.com
LPT108741 Terminated A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects with ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer
LPT109096 Completed Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer
LPT109098 Withdrawn A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Oral Topotecan in Combination with Lapatinib in Subjects with Advanced Solid Tumors
LPT109747 Completed An exploratory, phase II trial to determine the association of lapatinib induced fluoropyrimidine gene changes with efficacy parameters of lapatinib and capecitabine in first line gastric cancer
LPT111110 Terminated A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer
LPT111111 Active not recruiting LPT 111111- A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin bound Paclitaxel (nab-Paclitaxel or ABRAXANE®) and Lapatinib (TYKERB®) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer
MAB104954 Completed A study to optimise the propranolol block model for assessment of the pharmacological activity of bronchodilators in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MAB104958 Completed A study to assess the pharmacokinetics of single escalating doses of inhaled GSK961081 DPI (a dual pharmacophore) in healthy subjects (Part 1) and a randomised, double-blind, double dummy, crossover (incomplete block) study to assess the safety, tolerability, pharmacodynamics (pulmonary and systemic) and pharmacokinetics of 14 days dosing with inhaled GSK961081 DPI compared with placebo and tiotropium plus salmeterol in patients with COPD (Part 2) Study Listed on ClinicalStudyDataRequest.com
MAB108115 Completed A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt) Study Listed on ClinicalStudyDataRequest.com
MAB110123 Completed A randomized, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPD Study Listed on ClinicalStudyDataRequest.com
MAB110553 Completed A study to investigate the relative pharmacological activity of aninhaled B2-agonist/anticholinergic dual pharmacophore inhealthy volunteers Study Listed on ClinicalStudyDataRequest.com
MAD103894 Completed A 28 day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.
MAD105514 Completed A randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW679769 on polysomnographic sleep recordings, subjective sleep assessment, and daytime cognitive function in elderly and non-elderly subjects with primary insomnia
MAD105516 Completed A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 (10mg and 30 mg) on polysomnograph sleep recordings, subjective sleep assessment, daytime cognition and psychomotor function in subjects with primary insomnia
MAG103114 Completed A single-blind, single dose, placebo controlled, parallel group, first time in human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of ascending IV doses of GSK249320 in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
MD7108238 Completed A placebo-controlled, randomized, dose rising study to evaluate the safety, tolerability and pharmacokinetics of single and repeat ocular doses of pazopanib in healthy adult and elderly subjects.
MD7108240 Completed A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib drops, administered for 28 days to adult subjects with neovascular age-related macular degeneration.
MD7110861 Completed An open-label, two-period, fixed-sequence study in Healthy volunteers to evaluate the effects of repeat oral dosing of ketoconazole on the pharmacokinetics of a single dose of pazopanib (GW786034) administered as eye drops

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.